Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs
Molecules · 30.01.2023 · 28 (3) · 1324
DOI: 10.3390/molecules28031324 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 30.01.2023. Verfasst von Georgia Dorahy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia. Hauptthemen laut MEDLINE: Computer-Aided Design, Drug Design. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Training Program (RTP) scholarship, Australian Government RTP Scholarship, National Computational Merit Allocation Scheme.
Abstract (Originalsprache)
Central nervous system (CNS) disorders are a therapeutic area in drug discovery where demand for new treatments greatly exceeds approved treatment options. This is complicated by the high failure rate in late-stage clinical trials, resulting in exorbitant costs associated with bringing new CNS drugs to market. Computer-aided drug design (CADD) techniques minimise the time and cost burdens associated with drug research and development by ensuring an advantageous starting point for pre-clinical and clinical assessments. The key elements of CADD are divided into ligand-based and structure-based methods. Ligand-based methods encompass techniques including pharmacophore modelling and quantitative structure activity relationships (QSARs), which use the relationship between biological activity and chemical structure to ascertain suitable lead molecules. In contrast, structure-based methods use information about the binding site architecture from an established protein structure to select suitable molecules for further investigation. In recent years, deep learning techniques have been applied in drug design and present an exciting addition to CADD workflows. Despite the difficulties associated with CNS drug discovery, advances towards new pharmaceutical treatments continue to be made, and CADD has supported these findings. This review explores various CADD techniques and discusses applications in CNS drug discovery from 2018 to November 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
- Brain and Mind Centre, The University of Sydney, Camperdown, NSW 2050, Australia.
ORCID-Profile: Jake Zheng Chen
Förderung
- Research Training Program (RTP) scholarship
- Australian Government RTP Scholarship
- National Computational Merit Allocation Scheme
Zitieren
APA
Dorahy, G., Chen, J. Z., & Balle, T. (2023). Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs. Molecules, 28(3), 1324. https://doi.org/10.3390/molecules28031324
Vancouver
Dorahy G, Chen JZ, Balle T. Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs. Molecules. 2023;28(3):1324. doi:10.3390/molecules28031324
BibTeX
@article{Dorahy2023,
author = {Dorahy, Georgia and Chen, Jake Zheng and Balle, Thomas},
title = {Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs},
journal = {Molecules},
year = {2023},
volume = {28},
number = {3},
pages = {1324},
doi = {10.3390/molecules28031324}
}
EUVIMED